Long

HAVN -- Extremely oversold; 50% to most recent financing!

Updated

RSI below 20. Raised 11.5M at $1.07 in January and presents 50% discount at current levels. Good news flow. Psychedelics sector is getting some traction again.

Note

Allied Corp Signs Psilocybin Manufacturing Agreement To Produce Psilonex™ RX For What We Believe To Be The Largest Known Psilocybin Patient Cohort In The World

KELOWNA, British Columbia., June 29, 2021 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) an international medical company focused on creating and providing health solutions to address today’s medical mental health issues is pleased to announce the signing of a supply and manufacturing agreement with HAVN Life Sciences (CSE:HAVN or “HAVN”) to produce and distribute Psilonex™ RX psilocybin medical products for Allied’s patient cohort.

Allied has under provisional patent the formulation and trademark for Psilonex™ RX. Along with this, Allied has access to a cohort of over 300 veterans, police, fire and ambulance personnel who are struggling with post trauma symptoms and are requesting Psilonex™ RX. Allied will be caring for these patients under physician supervision and seeking Section 56 special access exemptions for the Allied patients in order to receive Psilonex™ RX products. Research and development will continue and data will be gathered to further provide foundation for future research and product development.

With Allied’s proprietary formulation for Psilonex™ RX, HAVN will produce bottles of Psilonex™ RX capsules ready to be dispensed upon legal and authorized prescription and in accordance with and subject to compliance of the Office of Controlled Substances of Canada. Psilonex™ RX is a proprietary formulation of psilocybin, cordyceps, lions mane, vitamin B and other ingredients.

“We have the patient cohort, the physician over-sight, the holistic nutritionists and psilocybin experts, the pharmacist scientists and physician research team all in place. The last piece of the puzzle was the manufacturer and supplier. With this now in place, we are ready to embark on providing legal psilocybin products to the largest patient cohort that we know of in the world. The significance that this represents to the global pharmaceutical markets of depression and anxiety is very exciting to say the least. Allied is at the forefront of this industry.” Says Calum Hughes, CEO of Allied Corp.

Note

HAVN Life Sciences Signs Finished Goods Supply Agreement with Allied Health

The Agreement will utilize HAVN Life's fully integrated supply chain model, from the growing of psilocybin through to extraction, compounding, and encapsulation

VANCOUVER, BC / ACCESSWIRE / June 29, 2021 / HAVN Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "HAVN Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is thrilled to announce it has entered into a supply agreement (the "Supply Agreement") with Allied Health (OTCQB:ALID), an innovator in the cannabis and psychedelics space, integrating medical research, cultivation and processing, and proprietary products and natural health product distribution.

Allied Health is in the process of developing Psilonex™ RX Capsules, a proprietary formulation of psilocybin, cordyceps, lion's mane, vitamin B, and other ingredients that will be available to their patient cohort, including more than 300 veterans, police, fire, and ambulance personnel struggling with PTSD and related mental health issues. Allied Health is currently seeking a Section 56 special access exemption for their patient cohort for the use of Psilonex™ RX Capsules, with continued research and data gathering planned for future product development.

"We are beyond excited to welcome Allied Health to our growing list of supply partners," says HAVN Life CEO, Tim Moore. "With a supply partner roster that includes Revive Therapeutics, The Heroic Hearts Project, Health Tech Connex, ATMA and now Allied Health, we are demonstrating industry support in our business model as an end-to-end supply chain for psychedelic compounds. With plans underway to have our Vancouver facility fully licenced and operational in the near future, this new aspect of production will be a tremendous revenue opportunity for us," he adds.

Pursuant to the Supply Agreement, Allied Health will have access to the Company's full range of psychedelic compounds and APIs, cultivated at the Company's facility in Jamaica, which opened this May. This Supply Agreement is a major milestone, marking the completion of HAVN Life's vision of a fully integrated supply chain model, from the growing of psilocybin, through to extraction, compounding and finally to encapsulation.

Allied Health's decision to use naturally derived psilocybin in their Psilonex™ RX Capsules underscores the growing patient preference for plant-based products over synthetic ones. By partnering with another industry innovator, HAVN Life further consolidates its position as an integral supply chain provider in respect of naturally-derived psychedelics for clinical providers and researchers around the globe.

With the recent news that California is moving toward decriminalizing psychedelics through Senate Bill 519 - Controlled substances: decriminalization of certain hallucinogenic substances, the growing demand for clinical and therapeutic use of psychedelic compounds is undeniable, and highlights HAVN Life's unique position as a source of safe and standardized products.

Any transactions to be completed pursuant to the Supply Agreement, including any supply of psilocybin thereunder, will be subject to compliance with any and all applicable laws and regulations, including those of Health Canada.

wealth_bakery

Also on:

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.